KR100307669B1 - Monoclonal Antibody-secreting Hybridoma for Detection of Lily Symptomless Virus and Preparation Method thereof and Monoclonal Antibodies - Google Patents
Monoclonal Antibody-secreting Hybridoma for Detection of Lily Symptomless Virus and Preparation Method thereof and Monoclonal Antibodies Download PDFInfo
- Publication number
- KR100307669B1 KR100307669B1 KR1019990005703A KR19990005703A KR100307669B1 KR 100307669 B1 KR100307669 B1 KR 100307669B1 KR 1019990005703 A KR1019990005703 A KR 1019990005703A KR 19990005703 A KR19990005703 A KR 19990005703A KR 100307669 B1 KR100307669 B1 KR 100307669B1
- Authority
- KR
- South Korea
- Prior art keywords
- lily
- monoclonal antibody
- virus
- lsv
- hybridoma
- Prior art date
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 16
- 230000003248 secreting effect Effects 0.000 title claims abstract description 5
- 241000710013 Lily symptomless virus Species 0.000 title abstract description 25
- 238000002360 preparation method Methods 0.000 title description 3
- 238000001514 detection method Methods 0.000 title 1
- 241000700605 Viruses Species 0.000 claims abstract description 33
- 241000234435 Lilium Species 0.000 claims abstract description 29
- 238000003556 assay Methods 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims abstract description 17
- 230000004927 fusion Effects 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 210000004698 lymphocyte Anatomy 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 6
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 12
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 5
- 230000008676 import Effects 0.000 abstract description 4
- 230000007910 cell fusion Effects 0.000 abstract description 3
- 241000894007 species Species 0.000 abstract description 2
- 230000006866 deterioration Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000003110 dot immunobinding assay Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000000464 low-speed centrifugation Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010029719 Nonspecific reaction Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 101100289061 Drosophila melanogaster lili gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000318998 Lily latent virus Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 210000000776 antibody secreting cell Anatomy 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
본 발명은 백합잠재바이러스(Lily symptomless virus, LSV)검정용 단크론 항체를 분비하는 융합세포인 하이브리도마(Hybridoma) 와 하이브리도마에 의해 분비되는 단크론 항체에 관한 것이다. 백합잠재바이러스는 백합을 재배하고 있는 세계 어느 지역에서나 보편적으로 감염되어 있으며, 이러한 바이러스 감염이 고품질 절화 백합생산은 물론, 백합생산을 위한 우량종구 생산의 제한요인이 되고있다. 본 발명은 세포융합기술을 이용하여 백합잠재바이러스에 대해 특이적으로 반응하는 단크론항체를 개발하여 대량의 시료에 대한 바이러스의 감염여부를 검정할 수 있도록 하고, 종래의 항체시약의 수입에 따른 비경제성과 수입시 수송도중에 야기되는 변질, 적기공급 등의 제반문제들을 해결할 수 있다.The present invention relates to a monoclonal antibody secreted by hybridomas and hybridomas, which are fusion cells secreting a monoclonal antibody for lily symptomless virus (LSV) assay. Lily potential viruses are common in all parts of the world where lilies are grown, and these infections are a limiting factor in the production of high-quality cut flowers, as well as the production of superior species for lily production. The present invention is to develop a monoclonal antibody that specifically reacts to the lily potential virus using cell fusion technology to test the infection of the virus to a large number of samples, and the economic effect of the import of conventional antibody reagent It can solve various problems such as deterioration and timely supply caused during transportation during performance import.
Description
본 발명은 백합잠재 바이러스(Lily symptomless virus, LSV)검정용 단크론 항체를 분비하는 융합세포인 하이브리도마(Hybridoma)와 그 제조방법 및 하이브리도마에 의해 분비되는 단크론항체에 관한 것이다.The present invention relates to hybridomas, fusion cells that secrete monoclonal antibodies for lily symptomless virus (LSV) assay, methods for their preparation, and monoclonal antibodies secreted by hybridomas.
백합잠재바이러스의 방제를 위해서는 바이러스의 감염유무를 정확하게 검정해야 한다. 특히 우량묘 생산시에는 대량의 시료를 간편하게 경제적으로 검정할 수 있는 검정시약이 필요한데 종래에는 이러한 검정용 항체시약을 대부분 외국에서 고가로 수입해서 쓰고 있어 경제적인 손실은 물론 수입에 따르는 문제점, 즉 수송도중에 변질하거나 적기공급이 원활하지 못할 경우도 있다. 따라서 본 발명자들은 농업과학기술원 식물병리과에서 1996년부터 2년간 연구를 수행, LSV 검정용 단크론항체를 생산하게 되었다.In order to control the lily potential virus, it is necessary to accurately test whether the virus is infected. In particular, during the production of high quality seedlings, an assay reagent that can easily and economically test a large amount of samples is required. In the past, such assay antibody reagents are mostly imported at a high cost from foreign countries. In some cases, it may deteriorate or the timely supply may not be smooth. Therefore, the inventors of the plant pathology department of Agricultural Science and Technology Institute conducted a study for 2 years from 1996, to produce a monoclonal antibody for LSV assay.
백합잠재바이러스는 백합을 재배하고 있는 세계 어느 지역에서나 보편적으로 감염되어 있다. 국내의 백합 재배지역 및 종구수입은 점차 늘어나는 추세이며 그 중요성도 높아지고 있으나, 바이러스 감염이 고품질 절화 백합생산은 물론, 백합수출을 위한 우량종구생산의 제한요인이 되고 있다. 최근에 많이 재배되고 있는 카사블랑카품종을 포장에서 임의 채취하여 조사한 결과 95%이상의 높은 감염율을 나타냈고, 기내에 들어있는 조직배양체에서도 약 30-60%정도의 감염율을 보였다. 이와같이 백합잠재 바이러스의 감염율이 높은 것은 백합은 조직배양 및 구근을 이용한 개체증식을 하므로 모본이 LSV에 감염되어 있을 경우 후대에까지 계속 감염되며 바이러스의 생물학적 특성상 약제방제가 불가능하기 때문이다. 이에 바이러스의 방제를 위해서는 바이러스의 감염여부를 정확하게 검정하여야 하는데, 이를 위해 본 발명의 목적은 항원인 백합잠재바이러스에 대한 항체를 하이브리도마에 의해 생산하고 항원 항체 반응을 이용하여 대량으로 백합잠재바이러스의 감염여부를 확인할 수 있도록 하는데 있다.Lily potential virus is common in all parts of the world where lily is grown. The import of lily cultivation area and species in Korea is increasing and its importance is increasing. However, virus infection has become a limiting factor for the production of high quality cut lilies as well as the production of high quality lily. In recent years, randomly harvested casablanca varieties from the field showed a high infection rate of more than 95%, and the tissue culture in the cabin showed an infection rate of about 30-60%. The high rate of infection of lily potential virus is because lily grows through tissue culture and bulb growth, so if the mother is infected with LSV, the infection continues until later and drug control is impossible due to the biological characteristics of the virus. In order to control the virus, it is necessary to accurately test whether the virus is infected. To this end, an object of the present invention is to produce an antibody against a lily potential virus, which is an antigen, by hybridomas, and to use the antigen antibody reaction in large quantities. It is to be able to check whether the infection is.
도 1은 백합에서 분리한 백합잠재 바이러스 전자현미경 사진1 is an electron micrograph of lily potential virus isolated from lily
도 2는 웨스턴 블랏(Western-blot)에 의한 백합잠재 바이러스 동정사진Figure 2 is a picture of Lili Potential virus by Western blot (Western-blot)
도 3은 하이브리도마가 분비하는 단크론항체와 백합잠재 바이러스의 결합반응 사진3 is a photograph of the binding reaction between the monoclonal antibody secreted by the hybridoma and lily potential virus
도 4는 단크론 항체를 이용한 백합조즙액 시료의 바이러스 검정사진Figure 4 is a virus assay picture of lily juice solution using a monoclonal antibody
본 발명은 백합잠재바이러스를 정제하는 단계, 이를 이용하여 동물면역실험에 의해 얻은 임파구세포를 종양세포와 융합하여 임파구세포와 종양세포의 유전적인 성질을 동시에 지닌 하이브리도마(Hybridoma)세포를 제작·선발·클로닝 (Cloning)하는 단계, 백합잠재바이러스 검정용 단크론항체의 정제 및 항체의 아이소타잎(Isotype)을 측정하는 단계, 단크론항체의 항원 결정기인식 실험단계, 단크론항체를 이용한 바이러스의 검정단계의 일련의 과정에 의해 얻어진 백합잠재바이러스(LSV)에 대한 특이항체를 분비하는 하이브리도마와 이에 의해 분비되는 단크론항체로 구성되어진다. 본 발명의 내용을 이루는 하이브리도마는 모노크론인 1G6-B1라인으로 백합잠재바이러스(LSV)검정용 단크론 항체를 분비하며, 미생물의 복원조건으로는 (1)복원제의 조성은 RPMI-1640 배양액(15% FBS, 100㎍/㎖ streptomycin과 penicillin첨가)이고 pH 7.0-7.4의 환경이며, (2)살균은 0.22㎛ membrane을 통과시킴에 의해 이루어지고, (3)온도는 섭씨 37℃ 로서 배지는 조성 및 pH에 있어서는 복원제와 동일하다.The present invention is to prepare a hybridoma cells having the genetic properties of lymphocytes and tumor cells by fusion of lymphocytes obtained by animal immunoassay with tumor cells using the step of purifying the lily potential virus. Selection and cloning step, purification of monoclonal antibody for lily potential virus assay and measuring isotype of antibody, antigen determinant recognition experiment step of monoclonal antibody, virus assay using monoclonal antibody It consists of hybridomas that secrete specific antibodies against lily potential virus (LSV) obtained by a series of steps and monoclonal antibodies secreted thereby. Hybridoma constituting the present invention is monoclonal 1G6-B1 line to secrete lily latent virus (LSV) test monoclonal antibody, and as a condition for restoring microorganisms (1) the composition of the recovery agent RPMI-1640 Culture medium (15% FBS, added 100μg / ml streptomycin and penicillin) and environment of pH 7.0-7.4, (2) Sterilization by passing through 0.22㎛ membrane, (3) Temperature at 37 ° C Is the same as the restoring agent in composition and pH.
미생물의 배양조건으로는 (1)온도: 37℃, (2)pH 7.0-7.4, (3)CO2: 5% 내외이며, 저장조건은 (1)배양액 : RPMI-1640 배양액 (20% FBS, 10% DMSO 첨가), (2)pH:7.0-7.4, (3)온도 : -196℃(액체질소통)이며, 보존상 특히 주의할 사항으로는 보존 1일 전에 -70℃에서 1일간 전처리하여야 한다. 미생물은 세포주은행을 기탁기관으로 하여 1999년 2월 19일에 기탁하였고, 수탁번호는 KCLRF-BP-00021이다.The culture conditions of microorganisms were (1) temperature: 37 ° C, (2) pH 7.0-7.4, (3) CO 2 : around 5%, and storage condition was (1) Culture medium: RPMI-1640 culture solution (20% FBS, 10% DMSO added), (2) pH: 7.0-7.4, (3) Temperature: -196 ℃ (Liquid communication). Precautions for preservation should be pretreated at -70 ℃ for 1 day before storage. do. The microorganisms were deposited on February 19, 1999 using the Cell Line Bank as a depositary institution. The accession number is KCLRF-BP-00021.
이하 더 구체적인 내용은 실시예와 시험예를 통하여 설명하고자 하나 본 발명의 내용이 실시예 및 시험예에 국한되는 것은 아니다.Hereinafter, more specific details will be described through Examples and Test Examples, but the content of the present invention is not limited to Examples and Test Examples.
<실시예 1> 항원의 준비Example 1 Preparation of Antigen
본 발명에 사용된 항원은 백합잠재바이러스(LSV)이며 정제방법은 다음과 같다.The antigen used in the present invention is lily potential virus (LSV) and the purification method is as follows.
1) 바이러스 이병엽 0.5그람(g)을 2밀리리터(㎖) 0.5몰 인산 완충액(pH 7.5)으로 마쇄하였다.1) 0.5 grams (g) of virus two lobes were crushed with 2 milliliters (ml) 0.5 mole phosphate buffer (pH 7.5).
2) 마쇄한 용액 체적의 25퍼센트가 되도록 사염화탄소를 첨가하였다.2) Carbon tetrachloride was added to 25 percent of the ground solution volume.
3) 10분간 저속원심분리(3,000회/분)후, 상층의 액체층만 분리하였다.3) After low speed centrifugation (3,000 times / min) for 10 minutes, only the upper liquid layer was separated.
4) 분리된 액체층에 4퍼센트에 해당하는 폴리에틸렌글리콜(PEG, 분자량 6,000)을 넣고 염화나트륨(NaCl)을 0.1몰이 되도록 첨가하여 4℃에서 1시간 동안 교반하였다.4) 4% polyethylene glycol (PEG, molecular weight: 6,000) was added to the separated liquid layer, and sodium chloride (NaCl) was added to 0.1 mol and stirred at 4 ° C. for 1 hour.
5) 10분간 원심분리(10,000회/분)후 침전물을 0.02몰의 인산완충액(pH 7.5)으로 희석하였다.5) After centrifugation (10,000 times / min) for 10 minutes, the precipitate was diluted with 0.02 mol of phosphate buffer (pH 7.5).
6) 4항과 5항을 반복하여 실시, 정제한 바이러스를 웨스턴블랏(Western-blot)으로 LSV임을 확인한 후(제2도 참조) 항원으로 사용하였다.(참고 : 바이러스전기영동 및 웨스턴블랏은 일반적인 방법에 따랐으며, 바이러스 동정을 위한 LSV 항체는 사노피 제품을 사용하였음)6) Repeated 4 and 5, the purified virus was confirmed as Western blot (LSV) (see Figure 2) was used as the antigen. (Note: Virus electrophoresis and Western blot is a general Method, and LSV antibody for virus identification was used Sanofi product)
<실시예 2> 동물면역Example 2 Animal Immunity
면역에 사용된 동물은 생후 약 6주된 암컷 밥씨(BALB/c) 마우스이며 항원인 LSV를 3회 복강주사했다. 주사간격은 1회와 2회 사이는 4주, 2회와 3회 사이는 1주 간격으로 실시하였다.Animals used for immunization were female Bob seed (BALB / c) mice about 6 weeks old and were intraperitoneally injected with the antigen LSV three times. The injection interval was 4 weeks between 1 and 2 times, and 1 week between 2 and 3 times.
<실시예 3> 세포융합Example 3 Cell Fusion
3회 면역 후 밥씨마우스의 임파구 세포와 종양세포인 엔에스-1(NS-1)세포를 50퍼센트 폴리에틸렌글리콜(PEG, 분자량 1,500)로 융합하여 임파구세포와 종양세포의 유전적인 성질을 동시에 지닌 융합세포인 하이브리도마(Hybridoma)를 제작하였다. 세포융합은 일반적인 방법에 따랐으며 하기와 같다.After three immunizations, fusion of Bob's mouse lymphocytes and tumor cells, NS-1 (NS-1) cells, with 50% polyethylene glycol (PEG, molecular weight 1,500) was performed to simultaneously combine the genetic properties of lymphocytes and tumor cells. Cell hybridomas were prepared. Cell fusion followed the general method and is as follows.
1) 임파구세포와 종양세포를 약 5:1의 비율로 알피엠아이-1640(RPMI-1640) 배양액 10밀리리터에 혼합하였다.1) Lymphocytes and tumor cells were mixed in 10 milliliters of RMP-1640 (RPMI-1640) culture at a ratio of about 5: 1.
2) 10분간 저속 원심(1,000회/분)하여 두 세포를 침전시켰다.2) The cells were precipitated by low speed centrifugation (1,000 times / minute) for 10 minutes.
3) 침전물에 50퍼센트 폴리에틸렌글리콜(PEG) 1밀리리터를 45초에 나누어 한방울씩 첨가하였다.3) One milliliter of 50% polyethylene glycol (PEG) was added to the precipitate in 45 seconds and added dropwise.
4) 섭씨 37도에서 75초간 놓아두었다가 2밀리리터 배양액을 60초간 첨가하였다.4) After 75 seconds at 37 degrees Celsius, 2 milliliter culture was added for 60 seconds.
5) 섭씨 37도에서 60초간 놓아둔 후 2밀리리터 배양액을 60초간 첨가하였다.5) After 60 seconds at 37 degrees Celsius, 2 milliliter culture was added for 60 seconds.
6) 섭씨 37도에서 60초간 놓아둔 후 20밀리리터 배양액을 120초간 첨가하였다.6) After 60 seconds at 37 degrees Celsius, 20 milliliter culture was added for 120 seconds.
7) 20밀리리터 배양액을 넣어둔 후 10분간 저속원심분리(1,000회/분)하였다.7) After 20 ml of the culture solution was added, low-speed centrifugation (1,000 times / minute) was carried out for 10 minutes.
8) 상부의 배양액을 제거한 후 침전물을 에이치에이티(HAT)배양액으로 혼합한 후 96공 배양플레이트에 분주하였다.8) After removing the culture medium from the top, the precipitate was mixed with HAT culture medium and dispensed into 96-hole culture plate.
9) 분주된 배양플레이트를 5퍼센트 탄산가스가 공급되는 항온기에서 배양하였다.(온도는 섭씨 37도로 조절)9) Aliquoted culture plates were incubated in a thermostat supplied with 5 percent carbon dioxide (temperature controlled at 37 degrees Celsius).
<실시예 4> 융합세포의 선발 및 클로닝Example 4 Selection and Cloning of Fusion Cells
효소연결 항체검정법(일라이저, ELISA)에 의해 1차로 선발된 융합세포중에서 5개 라인을 선발, 한계희석법(limiting dilution)에 의해 클로닝(cloning) 하였으며 그 방법은 하기와 같다.Five lines were selected from fusion cells selected first by enzyme-linked antibody assay (ELISA, ELISA) and cloned by limiting dilution.
1) 약 200개의 융합세포를 생후 3∼4주된 밥씨마우스의 흉선세포(thymus cell)와 알피엠아이(RPMI)-1640 배양액 40밀리리터로 혼합하고1) Mix about 200 fusion cells with 40 milliliters of thymus cells of RBM mice aged 3-4 weeks old and RPMI-1640 culture medium.
2) 혼합액을 두 개의 96공 배양플레이트에 분주한 후2) Dispense the mixed solution into two 96-hole culture plates
3) 분주된 세포를 5퍼센트 탄산가스가 공급되는 37℃ 항온기에서 배양하였다.3) The aliquoted cells were incubated in a 37 ° C thermostat supplied with 5% carbon dioxide gas.
4) 배양 10일째부터 세포의 성장상태를 검경, 재선발을 하였으며 재선발에 사용된 효소연결항체검정법(ELISA)은 하기와 같다.4) From the 10th day of culture, cell growth was examined and reselected. The enzyme-linked antibody assay (ELISA) used for reselection was as follows.
① 일라이저플레이트에 항원인 백합잠재바이러스와 건전대조구를 교대로 100 마이크로리터(㎕)씩 첨가하였고① 100 microliters (μl) of lily potential virus and whole control were added to the plate.
② 섭씨 37도에서 약 2시간(혹은 실온에서 약 3시간)놓아둔 후 0.02몰 피에치(pH) 7.4인 인산완충액으로 6회 세정하였다.② After about 2 hours (or about 3 hours at room temperature) at 37 degrees Celsius, it was washed six times with a phosphate buffer solution of 0.02 mol etch (pH) 7.4.
③ 1/2-스트랭스(1/2-strength) 카보네이트-바이카보네이트 완충액에 0.1 퍼센트 비에스에이(BSA)를 용해시킨 후 플레이트의 각 웰(well)에 100 마이크로리터씩 첨가하고③ Dissolve 0.1 percent BSA in 1 / 2-strength carbonate-bicarbonate buffer and add 100 microliters to each well of the plate.
④ ②번 과정을 반복하였다.④ Repeat step ②.
⑤ 항체분비유무를 검사하고자 하는 융합세포의 배양액을 50마이크로 리터씩 첨가하였고⑤ 50 microliters of culture medium of the fusion cells to be tested for antibody secretion was added.
⑥ ②번 과정을 반복하였다⑥ Repeated ②
⑦ 마우스이뮤노글로부린-지(IgG)에 반응하는, 알카라인포스파테이스 (alkaline phosphatase)로 연결된 2차항체를 첨가하였고(7) added a secondary antibody linked with alkaline phosphatase, which reacts with mouse immunoglobulin-ji (IgG)
⑧ ②번 과정을 반복하였다.⑧ Repeat step ②.
⑨ 기질인 4-니트로페닐포스페이트(4-nitrophenyl phosphate)를 반응시켰다⑨ 4-nitrophenyl phosphate as a substrate was reacted
⑩ 섭씨 37도에서 약 1시간(혹은 실온에서 약 2시간) 반응 후 발색반응을 보거나 파장 405 나노미터(㎚)에서 광흡수치를 측정하였다.37 After about 1 hour (or about 2 hours at room temperature) reaction at 37 degrees Celsius, the color reaction was observed or the light absorption value was measured at a wavelength of 405 nanometers (nm).
⑪ 건전대조구에는 무색으로 항원인 LSV에 대해서는 황색반응을 나타내는 세포주를 선발하거나, 파장 405나노미터(㎚)에서 건전대조구보다 2배이상 높은 광흡수치를 나타내는 세포주를 선발하였다.⑪ As a colorless, cell line showing a yellow response to the antigen-free LSV was selected, or a cell line showing a light absorption value more than two times higher than that of the sound control at wavelength 405 nanometers (nm).
(LSV에 대한 특이항체분비 융합세포주 저장보존) (Storage and storage of specific antibody secreting fusion cell line against LSV)
본 농업과학기술원에서 연구개발하여 액체질소통에 저장보존하고 있는 융합세포주는 아래와 같다 (표1 참조).The fusion cell lines researched and developed by the National Institute of Agricultural Science and Technology and stored and stored in liquid nitrogen communication are as follows (see Table 1).
표 1. 백합잠재바이러스와 반응하는 항체를 분비하는 융합세포 및 단크론항체라인Table 1. Fusion Cells and Monoclonal Antibody Lines Secreting Antibodies Responding to Lily Potential Virus
<실시예 5> 백합잠재바이러스 검정용 단크론항체 정제 및 항체의 아이쏘타잎 (isotype) 측정Example 5 Purification of Monoclonal Antibodies for Lily Potential Virus Assay and Isotype Measurement of Antibodies
액체질소통에 보존된 11개의 단크론항체 분비 세포주 중에서 1F2-B3라인과 1G6-B1라인을 배양, 배양상등액으로부터 일반적으로 많이 사용되고 있는 50% 암모늄썰페이트[(NH4)2SO4]를 사용하여 항체를 염석하고, 음이온교환수지, 투석 등의 방법을 이용하여 LSV 검정용 단크론 항체를 정제하였으며, 정제한 항체의 아이쏘타잎 측정은 시그마사의 마우스 단크론항체 아이쏘타잎 검정시약 (mouse monoclonal antibody isotyping reagents)을 사용하여 일라이저(ELISA)에 의해 측정한 결과는 다음과 같다 (표2 참조).Of the 11 monoclonal antibody-secreting cell lines preserved in liquid nitrogen communication, 1F2-B3 and 1G6-B1 lines were cultured and 50% ammonium sulphate [(NH 4 ) 2 SO 4 ], which is commonly used from the culture supernatant, was used. The monoclonal antibody for LSV assay was purified using anion exchange resin, dialysis, and the like, and the isocyta leaf assay of the purified antibody was performed using the mouse monoclonal antibody isota leaf assay reagent from Sigma. The results measured by ELISA using antibody isotyping reagents are as follows (see Table 2).
표 2. 모노클론 1F2-B3와 1G6-B1의 아이쏘타잎Table 2. Isotypes of Monoclones 1F2-B3 and 1G6-B1
(주) IgG = immunoglobulin GIgG = immunoglobulin G
<시험예 1> 단크론항체의 항원결정기 인식시험Test Example 1 Antigen Determinant Recognition Test of Monoclonal Antibodies
본 농업과학기술원에서 개발한 단크론항체가 항원인 LSV를 인식하는지 알아보기 위하여 디바(DIBA, dot immunobinding assay)에 의해 조사하였으며 방법은 하기와 같다.In order to determine whether the monoclonal antibody developed by the Institute of Agricultural Science and Technology recognizes the antigen LSV, it was investigated by DIBA (dot immunobinding assay). The method is as follows.
1) 니트로셀룰로오스페이퍼(nitrocellulose paper,NC paper)를 적당한 크기로 잘라서 0.05몰 티비에스(TBS)완충액에 5분동안 침적후 꺼내서 약 30분간 자연건조시켰다.1) Nitrocellulose paper (NC paper) was cut to a suitable size, immersed in a 0.05 mol TBS buffer solution for 5 minutes, taken out and dried for about 30 minutes.
2) NC페이퍼에 마이크로피펫을 사용하여 항원인 정제 LSV를 두번씩 (duplicate) 점적한 후, 실온에서 1시간동안 놓아두었다.2) The purified LSV, which is an antigen, was added to the NC paper by micropipette twice, and then left at room temperature for 1 hour.
3) 건전대조구도 LSV정제와 동일한 과정으로 준비된 항원을 사용하였다.3) Antigen prepared by the same process as LSV purification was used as a healthy control.
4) TBS로 10분씩 3회 세정하였다.4) Washed 3 times for 10 minutes with TBS.
5) TBS에 희석한 2% BSA로 37℃에서 1시간동안 블록킹(blocking)하였다.5) Blocked for 1 hour at 37 ° C. with 2% BSA diluted in TBS.
6) TBS로 10분씩 3회 세정하였다.6) washed three times with 10 minutes each TBS.
7) 효소 알카라인 포스파테이스(alkalinephosphatase)를 연결시킨 단크론항체(1G6-B1라인) 즉, 칸주게이트(conjugate)를 TBS에 100배로 희석하여 37℃에서 1시간동안 처리하였다.7) Monoclonal antibody (1G6-B1 line), that is, conjugated with the enzyme alkaline phosphatase (1G6-B1 line), the conjugate (conjugate) was diluted 100 times in TBS and treated for 1 hour at 37 ℃.
8) TBS로 10분씩 3회 세정한 후, 기질인 비씨아이피/엔비티(BCIP/NBT)를 처리하여 발색반응을 확인하였다.8) After washing three times with TBS for 10 minutes, the substrate was treated with BCIP / NBT (BCIP / NBT) to confirm the color reaction.
건전대조구에서는 반응하지 않았으나 도 3에서 나타난 바와같이 항원인 LSV와 희석배수 80배까지 결합반응하였다.It did not react in the healthy control, but as shown in FIG.
<시험예 2> 단크론항체를 이용한 바이러스 검정<Test Example 2> Virus assay using monoclonal antibody
도 3에서 본 바와 같이 단크론항체가 정제된 LSV 즉, 항원과 결합반응함이 확인되었으나, 대량의 시료를 간편하게 검정하기 위해 정제된 항원은 물론 불순물이 제거되지 않은 조즙액과도 정상적으로 반응하는지 알아보았다.As shown in FIG. 3, it was confirmed that the monoclonal antibody binds to the purified LSV, that is, the antigen. However, the monoclonal antibody normally reacts with the purified antigen as well as the juice from which the impurities are not removed in order to easily assay a large amount of samples. saw.
1) LSV 이병엽과 건전엽중량의 10배(w/v)에 해당하는 트리스 완충액(0.05, pH7.5)으로 마쇄한 조즙액을 별도의 정제과정 없이 직접 최종희석농도 20배에서 640배로 사용하였다.1) The crude juice triturated with Tris buffer solution (0.05, pH7.5) corresponding to 10 times (w / v) of LSV Lee Byung-yeop and dry whole leaf weight was used directly at the final dilution concentration of 20 times to 640 times without further purification. .
2) 상기 1)의 시료를 디바(DIBA, 실시예 4 참조)방법으로 바이러스 검정이 가능한지 조사하였다.2) The sample of 1) was examined whether the virus assay was possible by the DIBA method (see Example 4).
도 4에서 보는 바와같이 희석배수 20∼40배까지 불순물에 의한 비특이적 반응이 약간 나타났으나 희석배수가 높아지면서 비특이적 반응은 제거되었으며 640배까지 희석해도 바이러스검정이 가능했다. 이상의 결과로 본 농업과학기술원에서 개발한 단크론항체를 정제과정 없이 트리스완충액으로 마쇄한 백합조즙액을 640배까지 희석하여 반응시켜도 LSV 검정을 효율적으로 할 수 있음을 알 수 있다.As shown in FIG. 4, nonspecific reactions due to impurities were slightly up to diluting folds of 20 to 40 folds, but nonspecific reactions were removed as dilution folds increased, and virus assay was possible even when diluting up to 640 folds. As a result, LSV assay can be efficiently performed even if the monoclonal antibody developed by the Institute of Agricultural Science and Technology is diluted and reacted with 640 times of the lily crude juice triturated with Tris buffer without purification.
상기과정들에 의해 제조된 백합바이러스(LSV)에 대한 단크론항체를 시험해 본 결과 정제된 LSV 뿐만이 아닌 불순물이 제거되지 않은 조즙액과도 정상적으로 반응 즉, 정제과정없이 트리스 완충액으로 마쇄한 백합 조즙액을 640배까지 희석하여 반응시켜도 효율적으로 LSV를 검정할 수 있음이 확인됐다. 이로써 종래의 우량묘 생산시 문제가 되어왔던 LSV 감염여부에 대한 검정의 제반 문제점(항체시약의 수입에 따른 고비용, 수송도중의 변질우려 및 적기공급의 문제등)을 본 발명의 완성으로 인하여 대량의 시료를 간편하게 경제적으로 검정할 수 있다.As a result of testing the monoclonal antibody against the lily virus (LSV) prepared by the above procedures, the lily juice was normally reacted not only with the purified LSV but also with the juice from which impurities were not removed. It was confirmed that LSV can be efficiently assayed by diluting the reaction to 640 times. As a result, many problems of the test for LSV infection, which have been a problem in the production of superior seedlings (high cost due to import of antibody reagent, concerns about alteration during transportation and timely supply, etc.) due to the completion of the present invention, Samples can be easily and economically assayed.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990005703A KR100307669B1 (en) | 1999-02-20 | 1999-02-20 | Monoclonal Antibody-secreting Hybridoma for Detection of Lily Symptomless Virus and Preparation Method thereof and Monoclonal Antibodies |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990005703A KR100307669B1 (en) | 1999-02-20 | 1999-02-20 | Monoclonal Antibody-secreting Hybridoma for Detection of Lily Symptomless Virus and Preparation Method thereof and Monoclonal Antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20000056410A KR20000056410A (en) | 2000-09-15 |
KR100307669B1 true KR100307669B1 (en) | 2001-09-24 |
Family
ID=19574684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990005703A KR100307669B1 (en) | 1999-02-20 | 1999-02-20 | Monoclonal Antibody-secreting Hybridoma for Detection of Lily Symptomless Virus and Preparation Method thereof and Monoclonal Antibodies |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100307669B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103760346B (en) * | 2014-01-25 | 2015-06-24 | 云南省农业科学院生物技术与种质资源研究所 | Dot fluorescence immunoassay method for quantitatively detecting plant virus |
CN104122390B (en) * | 2014-04-14 | 2015-04-15 | 中国科学院寒区旱区环境与工程研究所 | Reagent card for detecting lily symptomless virus by adopting colloidal gold immunochromatographic assay and preparation method |
-
1999
- 1999-02-20 KR KR1019990005703A patent/KR100307669B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20000056410A (en) | 2000-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cambra et al. | Detection of plum pox potyvirus using monoclonal antibodies to structural and non‐structural proteins 1 | |
Kawamura et al. | A sensitive enzyme-linked immunosorbent assay of ochratoxin A based on monoclonal antibodies | |
DE3687884T2 (en) | MONOCLONAL ANTIBODIES AND METHOD FOR DETECTING MUSHROOM PATHOGENES. | |
US10428139B2 (en) | GM hybridoma cell, monoclonal antibody, kit and preparation method and use thereof | |
CN112175071A (en) | Preparation method of novel coronavirus spike protein monoclonal antibody | |
Rose et al. | Production of monoclonal antibodies for the detection of potato virus Y | |
EP0311383B1 (en) | Monoclonal antibody to methamphetamine, preparation of the same, assay method and assay kit of methamphetamine | |
Viswanathan | Detection of phytoplasmas associated with grassy shoot disease of sugarcane by ELISA techniques/Nachweis von Phytoplasmen, die mit der „grassy shoof “-Krankheit an Zuckerrohr assoziiert sind, mit Hilfe von ELISA-Methoden | |
US20230174676A1 (en) | Preparation and application of an intact recombinant antibody specific to clothianidin based on the identified variable region sequence | |
KR100307669B1 (en) | Monoclonal Antibody-secreting Hybridoma for Detection of Lily Symptomless Virus and Preparation Method thereof and Monoclonal Antibodies | |
Gumpf, DJ, Zheng, G. Moreno, P. and Diaz | Production and evaluation of specific monoclonal antibodies to citrus tristeza virus strains | |
CN108165533A (en) | Secrete the hybridoma cell strain of water resistant rice stripe mosaic viral monoclonal antibodies and its monoclonal antibody application | |
Zimmermann et al. | Production and Characterization of Monoclonal Antibodies Specific to Closterovirus‐like Particles Associated with Grapevine Leafroll Disease | |
Hilgert et al. | Monoclonal antibodies suitable for plum pox virus determination | |
Stace-Smith et al. | Monoclonal antibodies differentiate the weakly virulent from the highly virulent strain of Leptosphaeria maculans, the organism causing blackleg of canola | |
CN103910795B (en) | Anti-glass strangles monoclonal antibody and the application thereof of irido virus | |
JPH06153979A (en) | Monoclonal antibody against fish iridovirus, hybridoma for producing the antibody and production method | |
CN113307776B (en) | Preparation and application of bispecific antibody for recognizing albendazole and carbendazim | |
CN115028691B (en) | Independent quality control system for test paper, hybridoma cell strain, coated monoclonal antibody for quality control line and application of coated monoclonal antibody | |
CN102559602A (en) | Monoclonal antibody hybridoma cell line for secreting southern rice black-streaked dwarf resistant viruses and monoclonal antibody application thereof | |
Wu et al. | Strain differentiation of cucumber mosaic virus associated with banana mosaic disease in Taiwan | |
US8349569B2 (en) | Anti-fibronectin fragment monoclonal antibody | |
Zein | Detection and Diagnosis of Cucumber Mosaic Virus in Infected Plants Using Monoclonal Antibodies by Enzyme-linked Immunosorbent Assays | |
KR100481710B1 (en) | Novel isometric virus OMIV-II from diseased oyster mushroom and immunoassay kit for detecting the same | |
CN115894673A (en) | Antibody for resisting novel coronavirus and application of antibody in detection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
EXPY | Expiration of term |